MeVis Medical Solutions AG (FRA:M3V) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

What is MeVis Medical Solutions AG LT-Debt-to-Total-Asset?

MeVis Medical Solutions AG FRA:M3V 66 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates FRA:M3V with a GF Score™ of 66/100 and a GF Value™ of €22.72. The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. MeVis Medical Solutions AG's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

MeVis Medical Solutions AG's long-term debt to total assets ratio stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00).

MeVis Medical Solutions AG (FRA:M3V) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

MeVis Medical Solutions AG LT-Debt-to-Total-Asset Related Terms

MeVis Medical Solutions AG LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for MeVis Medical Solutions AG's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MeVis Medical Solutions AG LT-Debt-to-Total-Asset Chart

MeVis Medical Solutions AG Annual Data

Trend

Dec15

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

MeVis Medical Solutions AG Semi-Annual Data
	Jun16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

66GF Score

MeVis Medical Solutions AG FRA:M3V

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

MeVis Medical Solutions AG LT-Debt-to-Total-Asset Calculation

MeVis Medical Solutions AG's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2025 is calculated as

LT Debt to Total Assets (A: Sep. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2025 )	/	Total Assets (A: Sep. 2025 )
	=	0	/	25.886
	=	0.00

MeVis Medical Solutions AG's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0	/	23.162
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

MeVis Medical Solutions AG (FRA:M3V) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on MeVis Medical Solutions AG and its competitors.

Is MeVis Medical Solutions AG's LT-Debt-to-Total-Asset too high?

MeVis Medical Solutions AG's current LT-Debt-to-Total-Asset is 0.00. Overall, MeVis Medical Solutions AG has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.

How does MeVis Medical Solutions AG's LT-Debt-to-Total-Asset compare to VEEV and BTSG?

MeVis Medical Solutions AG's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Healthcare Providers & Services company?

A good LT-Debt-to-Total-Asset depends on the Healthcare Providers & Services industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on MeVis Medical Solutions AG and its competitors. MeVis Medical Solutions AG's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is MeVis Medical Solutions AG stock overvalued right now?

MeVis Medical Solutions AG (FRA:M3V) has a current LT-Debt-to-Total-Asset of 0.00. The stock's GF Value™ is €22.72, compared to a current price of €24.00 — trading 5.6% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. MeVis Medical Solutions AG's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For MeVis Medical Solutions AG (FRA:M3V), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MeVis Medical Solutions AG (FRA:M3V) Overvalued in 2026?

Based on GuruFocus' analysis, MeVis Medical Solutions AG stock appears to be overvalued. The current stock price of €24.00 is trading 5.6% above its estimated GF Value™ of €22.72.

Key valuation signals for FRA:M3V:

LT-Debt-to-Total-Asset: 0.00
GF Value™: €22.72 vs. price of €24.00 (5.6% above fair value)
GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the FRA:M3V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MeVis Medical Solutions AG Business Description

Industry Healthcare Healthcare Providers & Services

Comparable Companies XTER:AJ91 HAM:IS8 VEEV ASX:PME BTSG TEM HQY TSE:2413 HNGE TXG DOCS WAY HKSE:02228 PRVA HTFL NSE:IKS SZSE:300253 NSE:SAGILITY OMCL HKSE:01833

Other Exchanges 0HI7:UK M3V:Germany

Address Caroline-Herschel-Strasse 1, Bremen, DEU, 28359

Website http://www.mevis.de

MeVis Medical Solutions AG is a provider of medical software products. The company markets its products to equipment manufacturer of medical devices and providers of medical information technology platforms. Its segment includes Digital mammography and Other diagnostics. The Digital mammography segment develops and markets software products which assist in breast diagnostic imaging and intervention. Its Other diagnostics segment consists of digital radiology products. In addition, it also provides the general analysis of radiology images. The company's geographical area of operations includes the United States of America and Europe.

66GF Score

Get the complete analysis for FRA:M3V

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€24.00

Price

€22.72

GF Value

View FRA:M3V Analysis

See LT-Debt-to-Total-Asset data for all stocks →